Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Therapeutic area

Metabolism and nutrition disorders – page 8

  • 755 clinical trials
  • 276 recruiting
  • 239 conditions
  • 26 countries

Conditions in this area

239 conditions with trials, the busiest first

Obesity122Type 2 diabetes mellitus85Overweight58Type 1 diabetes mellitus41Endocrine ophthalmopathy26Metabolic dysfunction-associated steatohepatitis24Diabetes mellitus21Non-alcoholic steatohepatitis17Type IIa hyperlipidaemia15Glycogen storage disease type II14Hypercholesterolaemia14Diabetic neuropathy13Diabetic retinal oedema13Diabetic foot12Alpha-1 antitrypsin deficiency11Chronic kidney disease10Fabry's disease10Osteoporosis10Hypertriglyceridaemia9Hypoparathyroidism9Acromegaly8Adrenoleukodystrophy8Dyslipidaemia8Iron deficiency8+215

Clinical trials in Metabolism and nutrition disorders

755 trials across Europe, recruiting first

Type of trial
Recruitment status
Quick filters

755 clinical trials

Propionic acidaemia

Recruiting

A study to evaluate the long-term safety and effectiveness of mRNA-3927 in patients with Propionic Acidemia

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:0–17 years · 18–64 years
  • Substances:Modified Messenger Ribonucleic Acid Encoding Human Propionyl-Coenzyme A Carboxylase Alpha And Beta Subunits Encapsulated Into Lipid Nanoparticles
  • Sponsor:Moderna Inc.

Metabolic dysfunction-associated liver disease

Recruiting

N1T-MC-MALO: A Master Protocol for a Randomized, Controlled, Clinical Trial of Multiple Pharmacologic Agents in Adult Participants With Metabolic Dysfunction-Associated Steatotic Liver Disease Who Are at Increased Risk of Developing Major Adverse Liver Outcomes (SYNERGY-Outcomes); N1T-MC-TZ01 Tirzepatide in participants with high-risk MASLD; N1T-MC-RT01 Retatrutide in participants with high-risk MASLD

Investigational
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:LY3437943 sodium
  • Sponsor:Eli Lilly & Co.

Hyperparathyroidism secondary

Recruiting

Phase 3 Evaluation of Etelcalcetide for Secondary Hyperparathyroidism in Pediatric Patients with Chronic Kidney Disease on Hemodialysis

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:0–17 years
  • Substances:Etelcalcetide
  • Sponsor:Amgen Inc.

Glycogen storage disease type II

Recruiting

A Study of S-606001 Added to Enzyme Replacement Therapy for Patients with Late-Onset Pompe Disease

Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years
  • Sponsor:Shionogi B.V.

Endocrine ophthalmopathy

Recruiting

Study of K1-70 compared to placebo for patients with active thyroid eye disease from Graves' disease

Investigational
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Human IgG1 monoclonal antibody against thyrotropin receptor
  • Sponsor:Av7 Limited

Type IIa hyperlipidaemia

Recruiting

A Study of Enlicitide for Safety and Effectiveness in Children and Adolescents with Heterozygous Familial Hypercholesterolemia

Investigational
Countries:BelgiumBelgium
  • Participants:0–17 years
  • Sponsor:Merck Sharp & Dohme LLC

Alpha-1 antitrypsin deficiency

Recruiting

A study comparing under-the-skin and into-the-vein alpha1-proteinase inhibitor treatment in patients with alpha1-antitrypsin deficiency

InvestigationalNo placebo
Countries:DenmarkDenmark
  • Participants:18–64 years · 65+ years
  • Substances:Human ALPHA1-PROTEINASE inhibitor
  • Sponsor:Grifols Therapeutics LLC

Type 2 diabetes mellitus+2

Recruiting

Testing the Immune Response to Trivalent Inactivated Influenza Vaccine in People with Obesity and Type 2 Diabetes

Registered drugNo placebo
Countries:SwedenSweden
  • Participants:18–64 years · Healthy volunteers
  • Substances:INFLUENZA A VIRUS, A/CROATIA/10136RV/2023 (H3N2) LIKE STRAIN X-425A, INACTIVATED
  • Sponsor:Region Stockholm – SLSO

Hyperkalaemia

Recruiting

A study testing how well patiromer lowers high potassium levels in the blood in children under 12 years of age with hyperkalemia

InvestigationalNo placebo
Countries:BelgiumBelgium
  • Participants:0–17 years
  • Substances:Patiromer
  • Sponsor:Vifor Pharma Inc.

Diabetic neuropathy

Recruiting

A study testing capsaicin patches compared to placebo for patients with painful diabetic nerve damage to assess effects on nerve symptoms and nerve fibers

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Capsaicin
  • Sponsor:Deutsche Diabetes Forschungsgesellschaft e.V.

Acute myocardial infarction+1

Recruiting

Sodium-glucose cotransporter-2 inhibitor drug combination for patients with diabetes and heart attack to slow coronary artery disease progression

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Canagliflozin
  • Sponsor:Humanitas Mirasole S.p.A.

Porphyria non-acute

Recruiting

Long-term study of bitopertin safety and effectiveness in patients with erythropoietic protoporphyria or X-linked protoporphyria

InvestigationalNo placebo
Countries:BelgiumBelgium
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Bitopertin
  • Sponsor:Disc Medicine Inc.

Substances studied in this area

The therapies tested most often in Metabolism and nutrition disorders trials.

Semaglutide77 clinical trialsSodium Chloride25 clinical trialsDapagliflozin23 clinical trialsTirzepatide17 clinical trialsEmpagliflozin16 clinical trialsCagrilintide15 clinical trialsPlacebo15 clinical trialsColecalciferol14 clinical trialsMetformin12 clinical trials
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.